Advanced ER+/HER2- Breast Cancer
Conditions
Brief summary
This study is a multi-center, open label, phase Ib/II clinical trial aimed at evaluating the safety, preliminary efficacy characteristic and PK characteristics of QLS1304 in combined with endocrine therapy in ER+/HER2- breast cancer patients. This study was divided into two stages: combo dose escalation and dose expansion.
Interventions
DRUGQLS1304 tablet+Fulvestrant or QLC1401
QLS1304 combined with endocrine therapy
DRUGQLS1304 tablet+Fulvestrant，AI or QLC1401+CDK4/6i
QLS1304 combined with endocrine therapy
Sponsors
Qilu Pharmaceutical Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Volunteer to participate in this study, sign an informed consent form and have good compliance; 2. Age ≥ 18 years old, Male or female 3. ECOG score: 0-1 4. Expected survival ≥ 12 weeks 5. Local recurrent or metastatic advanced ER+/HER2- breast cancer confirmed by histopathology or cytopathology; 6. Failed to at least one therapy line of endocrine therapy ; 7. Baseline presence of at least one measurable lesion according to the RECIST v1.1; 8. The functional level of important organs is basically normal, meeting the requirements of the scheme; 9. Female subjects with fertility and male subjects must agree to use highly effective contraception during the study treatment period and within 180 days after the last medication; 10. Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation. 11. Volunteer to participate in this clinical trial, willing and able to follow the procedures related to clinical visits and research, understand the research procedures, and have signed informed consent.
Exclusion criteria
1. Subjects have received live or attenuated live vaccines within 4 weeks before the first use of the investigational drug. 2. Subjects have undergone major organ surgery within 4 weeks before the first use of the investigational drug. 3. Subjects require long-term or high-dose use of non-steroidal drugs. 4. Subjects have not recovered from adverse events (AEs) caused by previous anti-tumor treatment to ≤ grade 1. 5. Subjects have a known or suspected severe allergy to the investigational drug or any of its components. 6. Subjects have other active malignant tumors within 3 years before the first use of the investigational drug. 7. Subjects have brain metastases and/or carcinomatous meningitis or leptomeningeal disease. 8. Subjects have active tuberculosis, radiation pneumonitis, drug-induced pneumonitis, pulmonary fibrosis, or other diseases, symptoms, or signs of severe lung function impairment. 9. Subjects are unable to swallow tablets or had gastrointestinal abnormalities that the investigator assessed as potentially affecting drug absorption. 10. Subjects have a history of severe cardiovascular or cerebrovascular disease within 6 months before the first use of the investigational drug. 11. Subjects have a hypertension medial history that blood is not well controlled despite treatment with multiple antihypertension drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recommended Phase II Dose (RP2D) of QLS1304 in combo therapy | through study completion，an average of 2 years |
| objective response rate（ORR） | through study completion，an average of 2 years |
Countries
China
Outcome results
None listed